Lung Cancer Clinical Trial
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Summary
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor.
This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.
Eligibility Criteria
Inclusion Criteria:
Phase 1-Diagnosis of advanced or metastatic solid tumor; Phase 2-Diagnosis of NSCLC
Not amenable to treatment with curative intent
Adequate bone marrow and organ function
Exclusion Criteria:
Impaired heart function
Uncontrolled tumor in the brain
Other active cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 15 Locations for this study
Mobile Alabama, 36608, United States
Los Angeles California, 90095, United States
Pensacola Florida, 32503, United States
Chicago Illinois, 60611, United States
Evanston Illinois, 60201, United States
Minneapolis Minnesota, 55414, United States
Hackensack New Jersey, 07601, United States
Bronx New York, 10461, United States
Nashville Tennessee, 37203, United States
Dallas Texas, 75230, United States
Denton Texas, 76210, United States
Plano Texas, 75093, United States
Fairfax Virginia, 22031, United States
Winchester Virginia, 22601, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.